Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11019515 | Leukemia Research | 2018 | 6 Pages |
Abstract
The standard treatment of waldeyer's ring DLBCL remains controversial. This retrospective study was designed to evaluate the role of consolidation radiotherapy (RT) in patients with stage I/II diffuse large B-cell lymphoma (DLBCL) limited in Waldeyer's ring (WR). We included 72 patients, 42 were treated with immunochemotherapy alone (CT group) and 30 were treated with immunochemotherapy followed by radiotherapy (CTâ+âRT group). All patients received at least 3 cycles of R-CHOP regimen and achieved complete remission (CR) after immunochemotherapy. After 53 months median follow-up time, the 5-year progression-free survival (PFS) rates in CTâ+âRT group vs. CT group were 93.3% vs. 92.5% (Pâ=â0.896), the 5-year overall survival (OS) rates were 96.7% vs. 94.4% (Pâ=â0.649). Patients with oropharyngeal primary had relatively better 5-year PFS and OS rates compared to nasopharyngeal primary (PFS: 98.2% vs. 73.3%, pâ=â0.001; OS: 100% vs. 79.0%, pâ<â0.001). Moreover, the primary site was the only independent prognostic factor for PFS in the multivariate analysis (pâ=â0.012, HR 16.858 [95% CI: 1.883-150.933]).
Keywords
DLBCLIFRTWaldeyer’s ringCRUNHLPET-CTIPIECoGDFSPFsImmunochemotherapyDisease free survivalProgression free survivaloverall survivalpositron emission tomography-computed tomographyRadiotherapycomplete remissionWorld Health OrganizationInternational Prognostic Indexeastern cooperative oncology groupconfidence intervallactate dehydrogenaseLDHDiffuse large B-cell lymphomaNon-Hodgkin’s lymphomahazard ratioPerformance statusWHO
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Chunyan Li, Xuejun Ma, Ziqiang Pan, Fangfang Lv, Zuguang Xia, Kai Xue, Qunling Zhang, Dongmei Ji, Junning Cao, Xiaonan Hong, Ye Guo,